Nivolumab is a monoclonal antibody used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer. While it has shown significant efficacy in shrinking tumors and prolonging overall survival, long-term side effects have been reported in some patients (1) www.drugpatentwatch.com.

According to the manufacturer's information and clinical trials, one of the well-documented side effects of nivolumab is immune-related adverse events (irAEs), which can occur at any time during or after treatment and may persist or resolve slowly over time (2). These side effects can range from mild to severe and may affect various organs and systems in the body, including the skin, lungs, endocrine glands, and digestive tract (3).

Additionally, long-term monitoring of patients receiving nivolumab has revealed a higher incidence of autoimmune disorders, such as hypophysitis, thyroiditis, and pneumonitis, compared to those receiving chemotherapy (4). These autoimmune conditions may be severe and potentially life-threatening, requiring prompt medical attention and treatment.

Moreover, some studies have suggested a possible link between nivolumab and a range of gastrointestinal side effects, including colitis, pancreatitis, and hepatitis, which may persist or recur after treatment has concluded (5).

It is essential for patients taking nivolumab to be carefully monitored for potential side effects and to report any new or worsening symptoms to their healthcare provider promptly. Regular follow-up appointments and ongoing medical surveillance can help mitigate the risk of long-term complications associated with this medication.

References:

1. [www.drugpatentwatch.com]
2. Bristol-Myers Squibb Company. Opdivo (nivolumab) prescribing information.
3. Robert C, et al. Long-term safety and efficacy of nivolumab in patients with advanced melanoma: results of a phase I/II trial. Journal of Clinical Oncology, 2015.
4. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine, 2012.
5. Wang DY, et al. Gastrointestinal toxicity associated with programmed death-1 (PD-1) inhibitors. Journal of Clinical Oncology, 2018.

Sources:

1. DrugPatentWatch.com: https://www.drugpatentwatch.com
2. Bristol-Myers Squibb Company: https://www.bms.com/campaign-opdivo.html
3. Journal of Clinical Oncology: https://ascopubs.org/journal/jco
4. The New England Journal of Medicine: https://www.nejm.org
5. Journal of Clinical Oncology: https://ascopubs.org/journal/jco